Cooperativity of CD44 and CD49d in leukemia cell homing, migration, and survival offers a means for therapeutic attack

Journal of Immunology

Volumn 191, Issue 10, 2013, Pages 5304-5316

  Singh, Vibuthi ^a   Erb, Ulrike ^a   Zöller, Margot ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; FOCAL ADHESION KINASE 1; HERMES ANTIGEN; PAXILLIN; STEROID RECEPTOR COACTIVATOR 1; ANTINEOPLASTIC AGENT; CISPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CELL ADHESION; CELL HOMING; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SPLEEN; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; JURKAT CELL LINE; LEUKEMIA; METABOLISM; METASTASIS; SCID MOUSE; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTEGRIN ALPHA4; JURKAT CELLS; LEUKEMIA; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SPLEEN;

EID: 84887443235     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301543     Document Type: Article

References (67)

1. Haynes, B. F., M. J. Telen, L. P. Hale, and S. M. Denning. 1989. CD44: a molecule involved in leukocyte adherence and T-cell activation. Immunol. Today 10:423-428.
2. Ghaffari, S., F. Smadja-Joffe, R. Oostendorp, J. P. Lévesque, G. Dougherty, A. Eaves, and C. Eaves. 1999. CD44 isoforms in normal and leukemic hematopoiesis. Exp. Hematol. 27:978-993.
3. Jackson, D. G. 2009. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol. Rev. 230:216-231.
4. Lapidot, T., A. Dar, and O. Kollet. 2005. How do stem cells find their way home? Blood 106:1901-1910.
5. Jin, L., K. J. Hope, Q. Zhai, F. Smadja-Joffe, and J. E. Dick. 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12:1167-1174.
6. Krause, D. S., K. Lazarides, U. H. Von Andrian, and R. A. Van Etten. 2006. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12:1175-1180.
7. Konopleva, M. Y., and C. T. Jordan. 2011. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 29:591-599.
8. Misaghian, N., G. Ligresti, L. S. Steelman, F. E. Bertrand, J. Bäsecke, M. Libra, F. Nicoletti, F. Stivala, M. Milella, A. Tafuri, et al. 2009. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23:25-42.
9. Ten Cate, B., M. De Bruyn, Y. Wei, E. Bremer, and W. Helfrich. 2010. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr. Drug Targets 11:95-110.
10. Papayannopoulou, T., G. V. Priestley, B. Nakamoto, V. Zafiropoulos, and L. M. Scott. 2001. Molecular pathways in bone marrow homing: dominant role of a4b1 over b2-integrins and selectins. Blood 98:2403-2411.
11. Carstanjen, D., A. Gross, N. Kosova, I. Fichtner, and A. Salama. 2005. The α4β1 and α5β 1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells. Transfusion 45:1192-1200.
12. Qian, H., K. Tryggvason, S. E. Jacobsen, and M. Ekblom. 2006. Contribution of a6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with α4 integrins. Blood 107:3503-3510.
13. Peled, A., O. Kollet, T. Ponomaryov, I. Petit, S. Franitza, V. Grabovsky, M. M. Slav, A. Nagler, O. Lider, R. Alon, et al. 2000. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95:3289-3296.
14. Voermans, C., P. M. Rood, P. L. Hordijk, W. R. Gerritsen, and C. E. Van Der Schoot. 2000. Adhesion molecules involved in transendothelial migration of human hematopoietic progenitor cells. Stem Cells 18:435-443.
15. Christ, O., R. Kronenwett, R. Haas, and M. Zöller. 2001. Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells. Exp. Hematol. 29:380-390.
16. Zohren, F., D. Toutzaris, V. Klärner, H. P. Hartung, B. Kieseier, and R. Haas. 2008. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111:3893-3895.
17. Sahin, A. O., and M. Buitenhuis. 2012. Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells. Cell Adhes. Migr. 6:39-48.
18. Arroyo, A. G., J. T. Yang, H. Rayburn, and R. O. Hynes. 1999. α4 Integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity 11:555-566.
19. Sackstein, R. 2011. The biology of CD44 and HCELL in hematopoiesis: the "step 2-bypass pathway" and other emerging perspectives. Curr. Opin. Hematol. 18:239-248.
20. Delforge, M., V. Raets, V. Van Duppen, P. Vandenberghe, and M. Boogaerts. 2005. CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of α4β 1 and α5β1 integrins. Leukemia 19:57-63.
21. Rajasagi, M., A. Von Au, R. Singh, N. Hartmann, M. Zöller, and R. Marhaba. 2010. Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. J. Cell. Mol. Med. 14 (6B):1453-1467.
22. Lundell, B. I., J. B. McCarthy, N. L. Kovach, and C. M. Verfaillie. 1997. Activation of β1 integrins on CML progenitors reveals cooperation between β1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia 11:822-829.
23. Marhaba, R., P. Freyschmidt-Paul, and M. Zöller. 2006. In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur. J. Immunol. 36:3017-3032.
24. Aruffo, A., I. Stamenkovic, M. Melnick, C. B. Underhill, and B. Seed. 1990. CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303-1313.
25. Schofield, K. P., M. J. Humphries, E. De Wynter, N. Testa, and J. T. Gallagher. 1998. The effect of α4β1-integrin binding sequences of fibronectin on growth of cells from human hematopoietic progenitors. Blood 91:3230-3238.
26. Neri, P., and N. J. Bahlis. 2012. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr. Cancer Drug Targets 12:776-796.
27. Toole, B. P. 2004. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 4:528-539.
28. Siegelman, M. H., D. Stanescu, and P. Estess. 2000. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J. Clin. Invest. 105:683-691.
29. Zarbock, A., K. Ley, R. P. McEver, and A. Hidalgo. 2011. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 118:6743-6751.
30. Bourguignon, L. Y. 2008. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin. Cancer Biol. 18:251-259.
31. Fehon, R. G., A. I. McClatchey, and A. Bretscher. 2010. Organizing the cell cortex: the role of ERM proteins. Nat. Rev. Mol. Cell Biol. 11:276-287.
32. Howes, M. T., M. Kirkham, J. Riches, K. Cortese, P. J. Walser, F. Simpson, M. M. Hill, A. Jones, R. Lundmark, M. R. Lindsay, et al. 2010. Clathrinindependent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells. J. Cell Biol. 190:675-691.
33. Legg, J. W., C. A. Lewis, M. Parsons, T. Ng, and C. M. Isacke. 2002. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat. Cell Biol. 4:399-407.
34. Tsukita, S., S. Yonemura, and S. Tsukita. 1997. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem. Sci. 22:53-58.
35. Katzav, S. 2009. Vav1: a hematopoietic signal transduction molecule involved in human malignancies. Int. J. Biochem. Cell Biol. 41:1245-1248.
36. Keysar, S. B., and A. Jimeno. 2010. More than markers: biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 9:2450-2457.
37. Föger, N., R. Marhaba, and M. Zöller. 2000. CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur. J. Immunol. 30:2888-2899.
38. Mishra, J. P., S. Mishra, K. Gee, and A. Kumar. 2005. Differential involvement of calmodulin-dependent protein kinase II-activated AP-1 and c-Jun. N-terminal kinase-activated EGR-1 signaling pathways in tumor necrosis factor-α and lipopolysaccharide-induced CD44 expression in human monocytic cells. J. Biol. Chem. 280:26825-26837.
39. Rajasagi, M., M. Vitacolonna, B. Benjak, R. Marhaba, and M. Zöller. 2009. CD44 promotes progenitor homing into the thymus and T cell maturation. J. Leukoc. Biol. 85:251-261.
40. Calpe, E., C. Codony, M. J. Baptista, P. Abrisqueta, C. Carpio, N. Purroy, F. Bosch, and M. Crespo. 2011. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 118:4401-4410.
41. Wang, K. X., and D. T. Denhardt. 2008. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19:333-345.
42. Okada, M., Y. Wang, S. W. Jang, X. Tang, L. M. Neri, and K. Ye. 2009. Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res. 69:4043-4051.
43. Mitchell, D. M., and M. A. Williams. 2010. An activation marker finds a function. Immunity 32:9-11.
44. Rose, D. M., R. Alon, and M. H. Ginsberg. 2007. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol. Rev. 218:126-134.
45. Han, J., D. M. Rose, D. G. Woodside, L. E. Goldfinger, and M. H. Ginsberg. 2003. Integrin α4β1-dependent T cell migration requires both phosphorylation and dephosphorylation of the α4 cytoplasmic domain to regulate the reversible binding of paxillin. J. Biol. Chem. 278:34845-34853.
46. Zöller, M. 2011. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 11:254-267.
47. Davids, M. S., and J. A. Burger. 2012. Cell trafficking in chronic lymphocytic leukemia. Open J. Hematol. 3 (Suppl. 1).
48. Dai, Y., M. Rahmani, X. Y. Pei, P. Khanna, S. I. Han, C. Mitchell, P. Dent, and S. Grant. 2005. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105:1706-1716.
49. Boston, S. R., R. Deshmukh, S. Strome, U. D. Priyakumar, A. D. MacKerell, Jr., and P. Shapiro. 2011. Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer 11:7.
50. Zou, G. M. 2007. Cancer stem cells in leukemia, recent advances. J. Cell. Physiol. 213:440-444.
51. Konopleva, M., Y. Tabe, Z. Zeng, and M. Andreeff. 2009. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 12:103-113.
52. Bonig, H., K. L. Watts, K. H. Chang, H. P. Kiem, and T. Papayannopoulou. 2009. Concurrent blockade of α4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 27:836-837.
53. Redondo-Muñoz, J., E. Ugarte-Berzal, J. A. García-Marco, M. H. Del Cerro, P. E. Van Den Steen, G. Opdenakker, M. J. Terol, and A. García-Pardo. 2008. α4β1 Integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112:169-178.
54. Cantor, J. M., M. H. Ginsberg, and D. M. Rose. 2008. Integrin-associated proteins as potential therapeutic targets. Immunol. Rev. 223:236-251.
55. Matsunaga, T., F. Fukai, S. Miura, Y. Nakane, T. Owaki, H. Kodama, M. Tanaka, T. Nagaya, R. Takimoto, T. Takayama, and Y. Niitsu. 2008. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22:353-360.
56. Girbl, T., E. Hinterseer, E. M. Grössinger, D. Asslaber, K. Oberascher, L. Weiss, C. Hauser-Kronberger, D. Neureiter, H. Kerschbaum, D. Naor, et al. 2013. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer Res. 73:561-570.
57. Nishiya, N., W. B. Kiosses, J. Han, and M. H. Ginsberg. 2005. An α4integrinpaxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nat. Cell Biol. 7:343-352.
58. Hao, J. J., Y. Liu, M. Kruhlak, K. E. Debell, B. L. Rellahan, and S. Shaw. 2009. Phospholipase C-mediated hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. J. Cell Biol. 184:451-462.
59. Wong, N. K., J. C. Lai, N. Maeshima, and P. Johnson. 2011. CD44-mediated elongated T cell spreading requires Pyk2 activation by Src family kinases, extracellular calcium, phospholipase C and phosphatidylinositol-3 kinase. Cell. Signal. 23:812-819.
60. Zeng, Z., I. J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, D. Harris, O. Frolova, N. Hail, Jr., W. Chen, S. M. Kornblau, et al. 2006. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 66:3737-3746.
61. Zheng, J., J. D. Hu, Y. Y. Chen, B. Y. Chen, Y. Huang, Z. H. Zheng, and T. B. Liu. 2012. Baicalin induces apoptosis in leukemia HL-60/ADR cells via possible down-regulation of the PI3K/Akt signaling pathway. Asian Pac. J. Cancer Prev. 13:1119-1124.
62. Ferrer, P. E., P. Frederick, J. M. Gulbis, G. Dewson, and R. M. Kluck. 2012. Translocation of a Bak C-terminus mutant from cytosol to mitochondria to mediate cytochrome C release: implications for Bak and Bax apoptotic function. PLoS ONE 7:e31510.
63. Naor, D., S. B. Wallach-Dayan, M. A. Zahalka, and R. V. Sionov. 2008. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 18:260-267.
64. Zöller, M., N. Föhr, and K. Herrmann. 1998. Treatment of mice with anti-CD44 after allogeneic bone marrow cell transplantation is lethal. J. Leukoc. Biol. 63:175-189.
65. Avin, E., J. Haimovich, and N. Hollander. 2004. Anti-idiotype × anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma. J. Immunol. 173:4736-4743.
66. Shuptrine, C. W., R. Surana, and L. M. Weiner. 2012. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol. 22:3-13.
67. Koehn, T. A., L. L. Trimble, K. L. Alderson, A. K. Erbe, K. A. McDowell, B. Grzywacz, J. A. Hank, and P. M. Sondel. 2012. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front. Pharmacol. 3:91.